argenx Announced New Partnerships With Chugai and the Clayton Foundation for Research to Provide Access to Innovative Antibody Engineering Technologies
argenx (NASDAQ: ARGX) announced the expansion of its technology capabilities in antibody engineering through new partnerships with Chugai and the Clayton Foundation. The Company is also broadening its collaboration with Halozyme to enable subcutaneous delivery for three additional current or future argenx product candidates.
· 10/06/2020 05:26
argenx (NASDAQ:ARGX) announced the expansion of its technology capabilities in antibody engineering through new partnerships with Chugai and the Clayton Foundation. The Company is also broadening its collaboration with Halozyme to enable subcutaneous delivery for three additional current or future argenx product candidates. Through these partnerships, argenx gains access to innovative technologies to advance its differentiated pipeline and strengthen its position as a leader in immunology. "Our Immunology Innovation Program, through which we partner with leading academic researchers, has been foundational in building our pipeline. In keeping with our commitment to expand and strengthen this program, we continue to make investments in our portfolio of antibody technologies. These new partnerships are a key part of the strategy to broaden our capabilities in antibody engineering in order to address new targets and develop first-in-class medicines for patients who need them," commented Hans de Haard, Ph.D., Chief Scientific Officer of argenx. "Additionally, we announced the extension of our collaboration with Halozyme to secure our ability to offer subcutaneous delivery of current and future pipeline candidates. We are on a mission to improve the lives of people suffering from severe autoimmune diseases and cancer and believe that this long-term collaboration will allow us to reach the greatest number of patients." New Antibody Engineering Research Agreements argenx has entered into two new research agreements to broaden its antibody engineering capabilities. Through these agreements, argenx can access world-class Fc engineering technologies to expand the therapeutic properties of future antibody candidates that emerge from its Immunology Innovation Program. The technologies will complement argenx's current portfolio of Fc engineering technologies (NHANCE®, ABDEG™, POTELLIGENT®) and enable the Company to further differentiate and expand its pipeline of antibody candidates. argenx and Chugai have entered into a research license and option agreement under which argenx may access Chugai's SMART-Ig® ("Recycling Antibody" and part of "Sweeping Antibody" technology) and ACT-Ig® (Antibody half-life extending technology). argenx and the Clayton Foundation have entered into a non-exclusive research agreement under which argenx may access the Clayton Foundation's proprietary DHS mutations to extend the serum half-life of therapeutic antibodies. Expansion of Access to Halozyme's ENHANZE® Technology argenx and Halozyme are expanding the existing global collaboration and license agreement that was signed in February 2019. Under the newly announced expansion, argenx gained the ability to access Halozyme's ENHANZE® drug delivery technology for three additional exclusive targets upon nomination bringing the total to six potential targets under the collaboration. To date, two targets have been nominated including the human neonatal Fc receptor FcRn and complement component C2. ENHANZE® has demonstrated across five FDA-approved products the ability to remove traditional limitations on the volume of biologics that can be delivered subcutaneously, potentially shortening drug administration time, reducing healthcare practitioner time, and offering additional flexibility and convenience for patients.